• Explore /
  • Poster
  • / A subgroup with improved overall survival from the phase 2 IMPACT study: Maintenance therapy of metastatic colorectal cancer patients with the TLR-9 agonist MGN1703.

A subgroup with improved overall survival from the phase 2 IMPACT study: Maintenance therapy of metastatic colorectal cancer patients with the TLR-9 agonist MGN1703.

Abstract Poster

Authors

null

Jorge Riera-Knorrenschild

Universitätsklinikum Giessen und Marburg, Marburg, Germany

Jorge Riera-Knorrenschild , Dirk Arnold , Hans-Georg Kopp , Frank Mayer , Hendrik Kroening , Dieter Nitsche , Jan Kuhlmann , Reinhard Ziebermayr , Johannes Andel , Alfredo Zurlo , Burghardt Wittig , Werner Scheithauer , Hans-Joachim Schmoll

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Immunotherapy and Biologic Therapy

Clinical Trial Registration Number

NCT01208194

Citation

J Clin Oncol 33, 2015 (suppl; abstr 3049)

DOI

10.1200/jco.2015.33.15_suppl.3049

Abstract #

3049

Poster Bd #

375

Abstract Disclosures

Similar Posters

First Author: Annika Kurreck

First Author: Josep Tabernero

First Author: Marla Lipsyc-Sharf

First Author: Benoist Chibaudel